Literature DB >> 33552829

MiR-192-5p regulates the proliferation and apoptosis of cholangiocarcinoma cells by activating MEK/ERK pathway.

Chaofeng Tang1, Peng Yuan1, Jian Wang2, Yubo Zhang1, Xiaowei Chang3, Dong Jin1, Peng Lei1, Zhenhui Lu1, Bendong Chen1.   

Abstract

OBJECTIVE: Cholangiocarcinoma (CCA) is the second most common liver cancer, characterized by late diagnosis and fatal outcome. Although miR-192-5p has been shown to have a vital role in various cancers, its role in CCA is unknown. Here, we investigated the role of miR-192-5p in CCA cell proliferation and apoptosis, and elucidated its potential mechanism of action.
METHODS: The miR-192-5p expression in CCA tissues and cell lines was detected by real-time quantitative reverse transcription-polymerase chain reaction. Cell proliferation was analyzed using the cell counting Kit-8 and 5-bromodeoxyuridine staining assays, while apoptosis was examined by flow cytometry and the terminal deoxynucleotidyl transferase deoxyuridine triphosphate nick-end labeling assay. Western blot analysis was used to measure the expression of cell proliferation and apoptosis-related proteins, as well as MEK/ERK signaling pathway-related proteins.
RESULTS: MiR-192-5p was highly expressed in CCA tissues and cell lines. Overexpression of miR-192-5p significantly promoted CCA proliferation, and inhibited apoptosis. The MEK inhibitor, PD98059, reversed these miR-192-5p-induced effects on MEK/ERK signaling-associated protein expression, proliferation promotion, and apoptosis inhibition in TFK-1 cells.
CONCLUSION: MiR-192-5p promotes proliferation and suppressed apoptosis of CCA cells via the MEK/ERK pathway, which may be a potential therapeutic strategy for CCA treatment. © King Abdulaziz City for Science and Technology 2021.

Entities:  

Keywords:  Apoptosis; Cholangiocarcinoma; MEK/ERK; MiR-192-5p; Proliferation

Year:  2021        PMID: 33552829      PMCID: PMC7843823          DOI: 10.1007/s13205-021-02650-w

Source DB:  PubMed          Journal:  3 Biotech        ISSN: 2190-5738            Impact factor:   2.406


  43 in total

Review 1.  Cholangiocarcinoma - evolving concepts and therapeutic strategies.

Authors:  Sumera Rizvi; Shahid A Khan; Christopher L Hallemeier; Robin K Kelley; Gregory J Gores
Journal:  Nat Rev Clin Oncol       Date:  2017-10-10       Impact factor: 66.675

Review 2.  MicroRNAs as Potential Targets for Therapeutic Intervention With Metastasis of Non-small Cell Lung Cancer.

Authors:  Ulrich H Weidle; Fabian Birzele; Adam Nopora
Journal:  Cancer Genomics Proteomics       Date:  2019 Mar-Apr       Impact factor: 4.069

3.  RLIP76 is overexpressed in human glioblastomas and is required for proliferation, tumorigenesis and suppression of apoptosis.

Authors:  Qi Wang; Jun-Yu Wang; Xiao-Ping Zhang; Zhong-Wei Lv; Da Fu; Yi-Cheng Lu; Guo-Han Hu; Chun Luo; Ju-Xiang Chen
Journal:  Carcinogenesis       Date:  2012-12-30       Impact factor: 4.944

4.  An HNF4α-microRNA-194/192 signaling axis maintains hepatic cell function.

Authors:  Aoi Morimoto; Mana Kannari; Yuichi Tsuchida; Shota Sasaki; Chinatsu Saito; Tsuyoshi Matsuta; Tsukasa Maeda; Megumi Akiyama; Takahiro Nakamura; Masakiyo Sakaguchi; Nobukazu Nameki; Frank J Gonzalez; Yusuke Inoue
Journal:  J Biol Chem       Date:  2017-05-02       Impact factor: 5.157

Review 5.  Cholangiocarcinoma.

Authors:  Nataliya Razumilava; Gregory J Gores
Journal:  Lancet       Date:  2014-02-26       Impact factor: 79.321

Review 6.  Pathogenesis, diagnosis, and management of cholangiocarcinoma.

Authors:  Sumera Rizvi; Gregory J Gores
Journal:  Gastroenterology       Date:  2013-10-15       Impact factor: 22.682

7.  MORC2 promotes cell growth and metastasis in human cholangiocarcinoma and is negatively regulated by miR-186-5p.

Authors:  Guanqun Liao; Xiaopeng Liu; Dehai Wu; Fangting Duan; Xueyi Xie; Shunqian Wen; Yiqun Li; Shengping Li
Journal:  Aging (Albany NY)       Date:  2019-06-09       Impact factor: 5.682

Review 8.  Intrahepatic Cholangiocarcinoma: Continuing Challenges and Translational Advances.

Authors:  Alphonse E Sirica; Gregory J Gores; John D Groopman; Florin M Selaru; Mario Strazzabosco; Xin Wei Wang; Andrew X Zhu
Journal:  Hepatology       Date:  2019-03-25       Impact factor: 17.298

9.  Targeting MicroRNAs for personalized cancer therapy.

Authors:  Yiwei Li; Aamir Ahmad; Dejuan Kong; Bin Bao; Fazlul H Sarkar
Journal:  Med Princ Pract       Date:  2013-08-13       Impact factor: 1.927

10.  LncRNA FTX Contributes to the Progression of Colorectal Cancer Through Regulating miR-192-5p/EIF5A2 Axis.

Authors:  Kui Zhao; Zhenyu Ye; Yecheng Li; Chunyan Li; Xiaodong Yang; Qiang Chen; Chungen Xing
Journal:  Onco Targets Ther       Date:  2020-03-31       Impact factor: 4.147

View more
  3 in total

1.  MiR-192-5p Alleviated Fibrosis and Inflammatory Responses of Tendon Cells by Targeting NFAT5.

Authors:  Fan Gong; Xiaoliang Li; Hanling Zhang; Jianke Wu; Guoxu Ma; Bowen Zhang; Jian Gao; Yi Ding; Yonglu Huang; Kun Xia; Suoli Cheng; Xuebing Zhou; Jiandang Shi; Fei Zhao
Journal:  Comput Math Methods Med       Date:  2022-07-05       Impact factor: 2.809

2.  Long non-coding RNA WAC antisense RNA 1 mediates hepatitis B virus replication <em>in vitro</em> by reinforcing miR-192-5p/ATG7-induced autophagy.

Authors:  Minkai Cao; Deping Yuan; Hongxiu Jiang; Guanlun Zhou; Chao Chen; Guorong Han
Journal:  Eur J Histochem       Date:  2022-09-02       Impact factor: 1.966

3.  MiR-192/NKRF axis confers lung cancer cell chemoresistance to cisplatin via the NF-κB pathway.

Authors:  Yang Li; Lingling Zu; Heng Wu; Fang Zhang; Yaguang Fan; Hongli Pan; Xinxin Du; Fengjie Guo; Qinghua Zhou
Journal:  Thorac Cancer       Date:  2021-12-24       Impact factor: 3.500

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.